Managing Nausea from Lunesta (Eszopiclone)
If you experience nausea with Lunesta, contact your doctor immediately, as nausea and vomiting are listed as symptoms of severe allergic reactions that require emergency medical attention. 1
Immediate Assessment Required
The FDA labeling explicitly identifies nausea and vomiting as potential signs of serious anaphylactic/anaphylactoid reactions, which can include:
- Swelling of tongue or throat
- Trouble breathing
- Nausea and vomiting
These symptoms warrant emergency evaluation, particularly if occurring with other allergic manifestations. 1
Clinical Decision Algorithm
Step 1: Rule Out Serious Reactions
- Assess for concurrent symptoms of angioedema (tongue/throat swelling, dyspnea)
- If present → discontinue Lunesta immediately and seek emergency care
- If isolated nausea → proceed to Step 2
Step 2: Optimize Administration
The FDA label provides specific guidance:
- Do NOT take Lunesta with or right after a meal 1
- Take only immediately before bed on an empty stomach
- Food delays absorption and may increase gastrointestinal side effects
Step 3: Consider Alternative Hypnotics
If nausea persists despite proper administration, switching medications is appropriate. Based on the 2017 AASM guidelines and recent safety data:
Preferred alternatives with lower GI side effect profiles:
- Doxepin (3-6 mg): Associated with lower rates of adverse events including nausea compared to most other hypnotics 2
- Suvorexant or other DORAs: Different mechanism (orexin antagonism vs GABA modulation) may avoid GI effects 3, 4
Cross-tapering protocol (if switching from eszopiclone): Gradual dose reduction of 10-25% weekly while initiating alternative agent 5
Important Caveats
- Nausea is not listed among the common side effects of eszopiclone in clinical trials (which included unpleasant taste, dry mouth, drowsiness, dizziness, headache) 1, 6, 7
- The specific mention of nausea in the context of severe allergic reactions suggests this symptom should not be dismissed as benign
- Network meta-analysis data shows gaboxadol had highest nausea risk (RR 3.49), while eszopiclone was primarily associated with dysgeusia and dry mouth rather than nausea 2
Do Not Continue If:
- Nausea occurs with first dose (suggests hypersensitivity)
- Any signs of angioedema develop
- Symptoms worsen or include vomiting
The absence of nausea as a commonly reported side effect in extensive clinical trials 6, 7 combined with its prominence in the FDA's severe reaction warnings 1 suggests this symptom requires careful evaluation rather than symptomatic management alone.